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Abstract Background: Herbal remedies have been widely utilized in treating chronic 
hepatitis C (CHC) worldwide. Selecting appropriate outcomes to reflect both beneficial 
and harmful effects is a crucial step in designing randomized controlled trials (RCTs). 
This study evaluated the outcomes reported in RCTs on herbal remedies for CHC with 
comparison to the core outcomes recommended by the Cochrane Hepato-Biliary Group 
(CHBG), to check the consistency of the outcomes and to provide recommendation for 
future researches. 
Methods: A systematic literature search was conducted in Western and Chinese 
databases to identify RCTs on herbal remedies for adults with CHC. For each trial, all 
the outcomes reported in the results section were collected. Comparison between trial 
outcomes and CHBG core outcomes were evaluated and summarized with descriptive 
statistics. 
Results: A total of 116 RCTs involving 9154 participants were included; 27 outcomes 
were identified. Commonly reported outcomes included alanine aminotransferase (64 
trials, 55.2%), adverse events (58 trials, 50.0%), and end-of-treatment virological 
response (50 trials, 43.1%). All trials indicated that the herbal remedies under 
investigation had a positive effect and was markedly more effective than the control. 
Nearly half of the trials reported that the combination of herbal medicine and antiviral 
drugs could ameliorate adverse events. Very few trials reported primary core outcomes 
relating survival and quality of life. The most frequently reported core outcomes are 
non-serious adverse events (54 trials, 46.6%), viral response (27 trials, 23.3%), and 
biochemical response (24 trials, 20.7%). 
Conclusion: The variation and inconsistency in trial outcomes impedes research 
synthesis efforts, and indicate the need for comparable outcomes through the 
development of core outcome sets in CHC. The low concordance of outcome reporting 
could be improved by following CHBG core outcomes recommendation. 
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1.0 Introduction 
Hepatitis C virus (HCV) affects an estimated 180 million people globally,1 and is a 
known cause for chronic hepatitis, cirrhosis, and hepatocellular carcinoma.2,3 As in 
many other conditions, patients with HCV infection often seek complementary and 
alternative medicine (CAM) when they have experienced dissatisfaction or drug 
resistance to conventional therapy.4 Herbal intervention is a popular CAM therapy 
being frequently and widely used in Asia,5 and is playing an important role in CHC 
management in China. Herbal remedies include single herbal extracts (e.g., silymarin, 
oxymatrine), which usually extracted from native plants, and multiple-herbal formulas 
(e.g., classical formula, prescription modification according to the pattern identification, 
self-created herbal prescription from individual hospital). It could be administered in 
tablet, capsule, pill, decoction, or injection. Over recent decades, herbal remedies have 
been commonly used worldwide to treat various liver diseases in clinical practice due 
to their anti-inflammatory and antifibrotic effects, long-lasting liver protection after 
treatment, low cost, natural way of healing, and few adverse events.6,7 There has also 
been a substantial increase in effectiveness and efficacy studies of herbal remedy 
displaying hepato-protective effects against hepatitis C.8,9 The volume of publications 
indicate high scientific interest in this field. When stakeholders seek guidance from 
clinical research to make evidence-based decisions, the outcomes reported could 
become an essential role in drawing a more forceful and persuasive conclusion.10‒12 
Ideally, a meta-analysis will help answer the question of what is the best herbal remedy 
for CHC, or what are the significant beneficial or harmful effects. This requires the 
same outcome reporting and measurements. However, previously published literature 
in herbal remedies for CHC highlighted the lack of uniform outcome reporting and 
measurements in research data.13,14
The variations in outcome reporting limits research transparency, and may be 
misleading due to incomparability of trials, favoring ineffective interventions or 
underestimating adverse events. This contributes to the waste identified in research.15 
It is crucial to accurately measure and report the outcomes in a more consistent and 
comparable way.16,17 The aforesaid issue can be solved by the establishment of a core 
outcome set (COS), which is a set of minimum agreed and standardized collection of 
outcomes that should be measured and reported for a specific clinical area for all trials.18 
COS has been endorsed as a mean to collect the outcomes in a more comparable way 
and to reduce outcome heterogeneity, as well as to increase the relevance of research 
and reduce research waste through the involvement of key stakeholders (e.g., health-
care professionals, trialists, patients) in its development.19 Currently, there is no 
consensus among these stakeholders in what and how outcomes should be measured 
and reported in CHC randomized controlled trials (RCTs). But core outcomes for CHC 
recommended by Cochrane Hepato-Biliary Group (CHBG) is available online; Eight 
core outcomes have been recommended for use in systematic reviews (SRs) of CHC 
randomized clinical trials: all-cause mortality or hepatitis C-related morbidity, health-
related quality of life (QoL), serious adverse events (that is, any untoward medical 
occurrence that results in death, is life threatening, requires hospitalization or 
prolongation of existing hospitalization, results in persistent or significant disability or 
incapacity, or is a congenital anomaly or birth defect), mortality due to hepatitis C-
related liver disease, non-serious adverse events (any untoward medical occurrence in 
a participant or clinical investigation participant that does not meet the above criteria 
for a serious adverse event is defined as a non-serious adverse events), number of 
participants without histological improvement, number of participants without 
sustained virological response (SVR), and number of participants without 
normalization of transaminases.20 Obviously, the core outcomes recommended by 
CHBG is helpful for Cochrane SRs or other SRs in standardizing in the selection of 
outcomes for the summary of finding tables which summarize the evidence for 
important and critical outcomes.21
Nevertheless, unlike conventional intervention (e.g., interferon, direct antiviral 
agents) mainly focused in virological response and disease activity, herbal intervention 
addressed long-term adverse effects and QoL.22,23 Our study aimed to summarize and 
display the outcomes reported in RCTs using herbal remedies for CHC, with 
comparison to CHBG core outcomes, and to serve as a basis for the future development 
of COS of integrity of conventional and herbal interventions on treatment of CHC.
2.0 Methods
2.1 Search strategy
We conducted a literature search of the following electronic databases: Cochrane 
Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of 
Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, BIOSIS, SinoMed, 
China Network Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), and 
Wanfang Database, from their inception date onwards until August 29, 2018.
Our search strategy included the MeSH headings chronic hepatitis C, herbal 
medicine, Chinese medicine, silymarin, glycyrrhizin, oxymatrine, and plant materials. 
The reference lists of included studies were also searched for additional studies that 
may not be identified through database searches. SRs were cross-checked for missing 
studies. The full search strategy is presented in Supplementary Data 1.
2.2 Eligibility criteria and study selection
Eligible criteria were predetermined: (i) RCTs irrespective of blinding, language, year, 
and publication status; (ii) RCT was designed to compare herbal remedy with no 
intervention, placebo, non-specific interventions (vitamins), antiviral drugs either 
recommended in guidelines (e.g. interferon, ribavirin, and direct antiviral 
agents),22,24‒26 or commonly used drugs in clinical practice with potential antiviral 
effects. Co-interventions were allowed in the experimental and control groups provided 
that the co-interventions were administered equally to all the intervention groups of a 
trial; (iii) target population were adults with CHC, concomitant diseases such as 
cirrhosis, severe fibrosis, and hepatocellular carcinoma were also included; (iv) 
reporting at least one outcome.
Two authors (SBL and YXS) independently screened titles and abstracts for 
inclusion of potentially eligible studies. For multiple publications of the same trial, only 
the largest study with most data was included. The two authors resolved any difference 
in opinion through discussion. A third author (YQY) enabled a consensus when a 
disagreement still persisted. 
2.3 Data collection and management
Two authors (SBL and YXS) independently performed data extraction for eligible trials 
using a pre-piloted data collection form. The publication language, sample size, age, 
herbal interventions were collected to present the general characteristics of the included 
trials. Both dichotomous data and continuous data as reported anywhere in the article’s 
results text, tables, or figures were collected. 
Serum HCV RNA levels measured at various time points, including rapid 
virological response (RVR), early virological response (EVR), end-of-treatment 
virological response (ETVR), sustained virological response (SVR), were collected 
respectively as reported in the trials. Disagreements were resolved through discussion, 
or a third author (YQY) arbitrated if a variable was unclear. 
For each trial, we displayed all the outcomes reported in the results section, and 
presented the consistency between trial outcomes and CHBG core outcomes. We 
counted the number of core outcomes reported in each trial, and the proportion of trials 
that measured each core outcome. Additionally, the percentage of overlap in core 
outcomes in the RCTs and CHBG recommendations were reported. 
2.4 Assessment of methodological quality
Two authors (YQY and NL) independently assessed the methodological quality in the 
included trials using the Cochrane “Risk of bias” tool.27 This includes six main aspects: 
allocation sequence generation, allocation concealment, blinding, incomplete outcome 
data, selective data reporting, and other bias. We classified methodological quality as 
at overall low risk of bias only if all of the risk of bias sources described above were 
classified as at low risk of bias. We classified methodological quality as at overall high 
risk of bias if any of the risk of bias sources described above were classified as unclear 
risk of bias or high risk of bias.
3.0 Results
As shown in Fig. 1, we identified 1726 publications; after duplication, 1320 records 
remained and were included for screening. Title and abstract screening resulted in the 
inclusion of 308 studies for full-text screening. 
Figure 1  Flow diagram of literature search.
3.1 General characteristics 
One hundred and sixteen RCTs, reporting data from 9154 adult participants were 
included ranging from 18 to 79 years old. The first RCT for herbal intervention for 
chronic hepatitis C was published in 1993. There were 15 (12.9%) studies published in 
English, four of which were on Chinese medicine formulas, one was on Japanese herbal 
formula, and 10 were on herbal extracts. The rest were published in Chinese, 69 of 
which were on Chinese medicine formulas, and 32 were on herbal extracts. The 
included herbal remedies could be divided into three main categories: Chinese medicine 
formula (73 trials, 62.9%), Japanese herbal medicine (1 trial, 0.9%), and single herbal 
extract (42 trials, 36.2%) (Supplementary Data 2).
3.2 Risk of bias
The risk of bias of included trials is summarized in Table 1. Following the Cochrane 
“Risk of bias” tool assessment, the majority of trials are poorly designed and with low-
quality methodology. All included RCTs were classified as trials with overall high risk 
of bias.
Table 1  The risk of bias of included studies.
3.3 Outcomes reported in the included RCTs
A total of 27 unique outcomes were identified, and were inconsistently reported and 
measured among the 116 RCRs. Continuous variables were presented as mean 
with/without standard deviation, and dichotomous variables were described as number 
or percentage. We summarized all the reported outcomes and presented the results with 
descriptive statistics (Table 2).
Table 2  Outcomes reported in 116 trials evaluating herbal remedy for CHC.
Outcomes Number of RCTs (%)
Total bilirubin
Albumin
Viral load 
Rapid virological response
Early virological response
End-of-treatment virological response
Sustained virological response
Haluronic acid
Human laminin
Procollagen III
Collagen type IV
Historical activity index
Abdominal ultra-sonograms 
Quantitative serum ALT levels
Normalization rate of ALT
Quantitative serum AST levels
Normalization rate of AST
22 (19.0)
5 (4.3)
22 (19.0)
2 (1.7)
20 (17.2)
50 (43.1)
27 (23.3)
23 (19.8)
22 (19.0)
23 (19.8)
18 (15.5)
2 (1.7)
6 (5.1)
64 (55.2)
23 (19.8)
43 (37.1)
6 (5.2)
Liver fibrosis SSS score
Health-related quality of life
Non-serious adverse events
Serious adverse events
Mortality 
Hematological tests
1 (0.9)
7 (6.0)
58 (50.0)
4 (3.4)
2 (1.7)
17 (14.7)
Domains Low (%) High (%) Unclear (%)
Allocation sequence generation   
Allocation concealment
Blinding 
Incomplete outcome data 
Selective data reporting 
Other bias
21 (18.1)
3 (2.59)
16 (13.79)
18 (15.52)
110 (94.83)
113 (97.41)
95 (81.9)
112 (96.55%)
95 (81.9)
7 (6.03)
1 (0.86)
3 (2.59)
0
1 (0.86)
5 (4.31)
91 (78.45)
5 (4.31)
0
Immunological tests
Pharmacokinetics
Clinical symptoms
Kidney function tests
4 (3.4)
1 (0.9)
16 (13.8)
3 (2.6)
Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, SSS: 
semiquantitative scoring system.
Commonly reported outcomes included quantitative serum alanine 
aminotransferase (ALT) level (64 trials, 55.2%), type and number of participants with 
adverse events (58 trials, 50%), number of participants achieved ETVR (50 trials, 
43.1%), quantitative serum aspartate aminotransferase (AST) level (43 trials, 37.1%), 
number of participants achieved SVR (27 trials, 23.3%), and number of participants 
with normalization of ALT level (23 trials, 19.8%). The least reported outcomes (≤five 
trials) were albumin (five trials, 4.3%), serious adverse events (four trials, 3.4%), 
immunological tests (four trials, 3.4%), kidney function tests (three trials, 2.6%), RVR 
(two trials, 1.7%), historical activity index (two trials, 1.7%), liver fibrosis 
semiquantitative scoring system score (one trial, 0.9%), mortality (one trial, 0.9%), and 
pharmacokinetics (one trial, 0.9%). 
Serious adverse events were reported in four English-published trials (3.4%), 
including death from hepatocellular carcinoma (n = 1), withdrew because of severe 
irritability (n = 3), and withdraw because of severe depression (n = 8), respectively. 
One trial indicates there were no serious adverse events (n = 0). QoL was reported by 
seven trials published in English (6%) using seven different outcome measures 
including Quality of Life Questionnaire (HQLQ), the Short-Form 36 (SF-36), Self-
rating Depression Scale (SDS), the Center for Epidemiologic Studies-Depression 
(CES-D) Scale, self-administered quality-of-life WHOQOL-BREEF, Chronic Liver 
Disease Questionnaire (CLDQ), and The Arizona Sexual Experience Scale (ASEX). 
The term “therapeutic efficacy”, described as a “compound outcome”, was reported in 
39 trials (33.6%), and the measurements were found to be variable. Some trials defined 
the “therapeutic efficacy” as the elimination of clinical symptoms plus the 
normalization of biochemical response; some defined the “therapeutic efficacy” as loss 
of detectable HCV RNA (and/or serum anti-HCV) plus normalization of serum ALT 
level; some used self-defined scoring systems. 
All trials indicated that herbal intervention had a positive effect and were 
significantly more effective than the control group. Nearly half of the trials reported 
that the combination of herbal remedy and antiviral drugs can alleviate adverse events 
(e.g., alleviate myelosuppression); 23 trials (19.8%) reported that herbal intervention 
can delay the progression of liver fibrosis; seven trials (6.0%) used patient reported 
outcomes, and showed herbal intervention greatly improved clinical symptoms (e.g., 
fatigue, abdominal distention).
3.4 Comparison with CHBG core outcomes
Tables 3 and 4 presented the comparison between outcomes reported in RCTs and 
outcomes recommended by CHBG. Nearly one-third of the trials reported none of the 
eight CHBG core outcomes; 46 trials (39.7%) only reported one of the CHBG core 
outcomes; 23 trials (19.8%) reported two of the CHGB core outcomes; six trials (5.2%) 
reported three of the CHBG core outcomes; four trials (3.4%) reported four of the 
CHBG core outcomes, which was the biggest number of CHGB core outcomes reported 
among the included 116 trials. The most frequently reported core outcome by trialists 
is non-serious adverse events (54 trials, 46.6%). Although most of the trials reported 
serum HCV RNA load, but only in 27 trials (23.3%), HCV RNA was measured at 12 
and 24 weeks after end of treatment and reported in dichotomous data as CHBG defined. 
The third frequently reported core outcome was the number of participants without 
normalization of transaminases (24 trials, 20.7%). Three primary core outcomes, all-
cause mortality/hepatitis C-related morbidity, health-related QoL, and serious adverse 
events were reported in two trials, seven trials, and four trials respectively. Two trials 
reported the number of participants without histological improvement, and both of them 
were measured with historical activity index. None of the trials reported hepatitis C-
related mortality. 
Table 3  Number of trials reported on the CHBG core outcome.
CHBG core outcomes Trials 
(%)
All-cause mortality or hepatitis C-related morbidity
Health-related quality of life
Serious adverse events
Mortality due to hepatitis C-related liver disease
Non-serious adverse events
Number of participants without histological improvement
Number of participants without sustained virological response
Number of participants without normalisation of transaminases
2 (1.7)
7 (6.0)
4 (3.4)
0 (0)
54 (46.6)
2 (1.7)
27 (23.3)
24 (20.7)
CHBG: Cochrane Hepato-Biliary Group.
Table 4  Number of CHBG core outcome reported in RCTs.
Number of CHBG core outcomes Trials (%)
Number of trials reported zero core outcome
Number of trials reported one core outcome
Number of trials reported two core outcome
Number of trials reported three core outcome
Number of trials reported four core outcome
37 (31.9)
46 (39.7)
23 (19.8)
6 (5.2)
4 (3.4)
CHBG: Cochrane Hepato-Biliary Group.
4.0 Discussion 
4.1 Main findings
With the development of evidence-based medicine and the establishment of the Oxford 
Evidence Pyramid, SRs, meta-analyses, and RCTs have become the best source of 
evidence for modern medical guidelines and clinical practice. The published RCTs on 
herbal remedy for CHC showed the methodological quality are overall poor, and a huge 
heterogeneity of the outcome reporting and measurements, which may limit the 
between-study comparison and delay the progress of evidence collection.
Many Chinese trials used composite outcomes based on patient reported 
questionnaires about efficacy or symptoms relief, all with varying definitions. Different 
trialists encompassed the same concept (e.g. therapeutic efficacy) with different 
components, leading to variation in the definition criteria. Moreover, these composite 
outcomes lack reliability, and therefore they are not accepted internationally. The 
heterogeneity between definitions and the unreliability of composite outcomes make it 
difficult to synthesize and compare the beneficial and harmful effects, thus the RCT 
results could not be meta-analyzed, or the RCT results for different interventions could 
not be compared horizontally. Only seven English-published trials used international 
scale to measure QoL. The advantages of traditional Chinese medicine such as 
improving clinical symptoms, QoL, and reduce side-effects were not well reflected in 
the included trials. Obvious discrepancies between outcomes reported in RCTs and core 
outcomes recommended by CHBG for SRs were observed. Outcomes in the 
randomized trials on CHC should be primarily related to survival and disease 
progression according to CHBG, but the majority of current trials failed to 
comprehensively addressed mortality, liver-related morbidity, or QoL. 
The lack of consensus regarding the measurement and reporting of outcomes affect 
trial design, conduct, and analysis.28 Therefore, it is necessary to establish the minimum 
outcomes that conforms to the characteristics of traditional Chinese medicine (e.g., 
herbal remedy), and to develop a COS that should be collected in a standardized way 
and reported consistently in any publications.29,30 COS has been internationally 
regarded as a means to reduce outcome heterogeneity, thus to reduce research waste 
among similar studies.
4.2 Strength and limitations
Our study used a robust search strategy to collect outcomes reported internationally and 
nationally in RCTs of herbal remedy for CHC. To our knowledge, this is the first study 
to systematically overview the outcomes reported in trials and compare them with the 
core outcomes recommended by CHBG. This study can serve as a basis for developing 
a COS for clinical trials and researchers for CHC and herbal remedies. 
There are limitations that should be considered when interpreting these results. 
First, we included published RCTs, but did not include outcomes reported from 
unpublished trials and observational studies. Second, we focused on trials evaluating 
herbal remedies, but did not evaluate outcomes reported using other pharmacological 
interventions. Third, many of the included trials ambiguously defined composite 
outcomes, making it difficult to make judgments about whether differences were 
accurately presented. 
4.3 Implication for practice and research
Trialists and journal editors should be reminded that most individual RCTs may well 
be incorporated into subsequent SRs. Outcomes that did not reflect the priority of 
stakeholder groups or did not match internationally recommended core outcomes, may 
not always matter when interpreting a single trial result, but can have significant impact 
when synthesizing data of multiple randomized trials (e.g. meta-analysis).31
Protocols should be made publicly available.32,33 Prespecified outcomes can help 
protect against data dredging, in which only positive or favorable outcomes are reported, 
while negative or unfavorable outcomes are obscured.18 We suggest that journal editors 
be more vigilant and mandatory about registration policies when they receive the RCT 
submission. This may help alleviate the heterogeneity of future outcome reporting. 
It is important to acknowledge the therapeutic advantages of herbal remedy and 
antiviral drugs. The long-term effect in anti-inflammatory and liver protecting relates 
to functional items (e.g., physiological symptoms) and composite measures of QoL.34 
Internationally recognized QoL scales (e.g., SF-36, CLDQ) should be measured and 
reported instead of patient reported questionnaires designed by individual 
trialists/hospitals.
The Cochrane SRs form the highest level of evidence and are the most valuable 
source of information for health interventions. Therefore, until a COS is finalized, we 
encourage trialists and researchers select prespecified outcomes with reference to the 
core outcomes recommended by CHBG. This will be effective in improving the 
scientific possibility of comparing and summarizing outcomes from different trials and 
will maximize the research contribution of SRs and meta-analyses. 
Core outcomes are a recommended set of minimum outcomes that should be 
reported. However, it should be acknowledged that trialists and researchers, depending 
on the scope and the objective of the study, are not limited to report only these core 
outcomes. 
5.0 Conclusion 
The variation in outcomes measurements and reporting leads to multidirectional 
research, and makes the combination and comparability of the results impossible 
because of outcome heterogeneity. There is an urgent need for accurate reporting and 
measurement of consistent comparable outcomes through the development of a COS in 
CHC. The low concordance of outcome reporting could be improved by following the 
core outcome recommendation from CHBG. 
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Supplementary Table 2  Herbal remedies in the included RCTs.
 
TCM: traditional Chinese medicine. 
Category Herbal remedies RCTs (%)
Chinese medicine formula
Japanese herbal medicine
Single herbal extract
TCM decoction without name
Binggan Heji Decoction
Xiao Chai Hu Decoction
Song Zhi Pill
Diqin Guben Oral Liquid
Chaihu Shugan Powder
Er Gu Decoction
Fufang Danshen Tablet
Qishen Erlian Decoction
Qi Zhu Granule
Jianpi Moji Decoction
Anluo Huaxian Pill
Baogan Fugan Pill
Bing Gan Granule
Binggan Yihao Decoction
Gan Shu Capsule
Shenqi Fugan Capsule
Chai Shao Liu Jun Zi Decoction
Dahuang Shuchong Pill
Fuzhen Huayu Capsule
Yin Chen Hao Decoction
Shu Gan Capsule
Li Gan Long Granule
Hu Gan Ning Tablet
Shugan Jianpi Decoction
Jianpi Huoxue Decoction
Jianpi Bushen Decoction
Jiedu Huagan Decoction
Ganpi Tiaobu Decoction
CH100 Tablet
Kuan Sin Yin Decoction
Ninjinyoeito Granule
Oxymatrine Capsule
Oxymatrine Injection
Glycyrrhizin Tablet
Glycyrrhizin Injection
Glycyrrhizin Capsule
Silymarin Tablet
Silibinin Capsule
Silibinin Injection
28 (24.1)
3 (2.9)
3 (2.9)
3 (2.9)
3 (2.9)
3 (2.9)
2 (1.7)
2 (1.7)
2 (1.7)
2 (1.7)
2 (1.7)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
1 (0.9)
5 (4.3)
19 (16.4)
2 (1.7)
7 (6)
1 (0.9)
5 (4.3)
2 (1.7)
1 (0.9)
Table 1  The risk of bias of included studies.
Domains Low (%) High (%) Unclear (%)
Allocation sequence generation   
Allocation concealment
Blinding 
Incomplete outcome data 
Selective data reporting 
Other bias
21 (18.1)
3 (2.59)
16 (13.79)
18 (15.52)
110 (94.83)
113 (97.41)2
95 (81.9)
112 (96.55%)
95 (81.9)
7 (6.03)
1 (0.86)
3 (2.59)
0
1 (0.86)
5 (4.31)
91 (78.45)
5 (4.31)
0
Table 2  Outcomes reported in 116 trials evaluating herbal remedy for CHC.
Outcomes Number of RCTs (%)
Total bilirubin
Albumin
Viral load 
Rapid virological response
Early virological response
End-of-treatment virological response
Sustained virological response
Haluronic acid
Human laminin
Procollagen III
Collagen type IV
Historical activity index
Abdominal ultra-sonograms 
Quantitative serum ALT levels
Normalization rate of ALT
Quantitative serum AST levels
Normalization rate of AST
22 (19.0)
5 (4.3)
22 (19.0)
2 (1.7)
20 (17.2)
50 (43.1)
27 (23.3)
23 (19.8)
22 (19.0)
23 (19.8)
18 (15.5)
2 (1.7)
6 (5.1)
64 (55.2)
23 (19.8)
43 (37.1)
6 (5.2)
Liver fibrosis SSS score
Health-related quality of life
Non-serious adverse events
Serious adverse events
Mortality 
Hematological tests
Immunological tests
Pharmacokinetics
Clinical symptoms
Kidney function tests
1 (0.9)
7 (6.0)
58 (50.0)
4 (3.4)
2 (1.7)
17 (14.7)
4 (3.4)
1 (0.9)
16 (13.8)
3 (2.6)
Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, 
SSS: semiquantitative scoring system.
Table 3  Number of trials reported on the CHBG core outcome.
CHBG core outcomes Trials 
(%)
All-cause mortality or hepatitis C-related morbidity
Health-related quality of life
Serious adverse events
Mortality due to hepatitis C-related liver disease
Non-serious adverse events
Number of participants without histological improvement
Number of participants without sustained virological response
Number of participants without normalisation of transaminases
2 (1.7)
7 (6.0)
4 (3.4)
0 (0)
54 (46.6)
2 (1.7)
27 (23.3)
24 (20.7)
CHBG: Cochrane Hepato-Biliary Group.
Table 4  Number of CHBG core outcome reported in RCTs.
Number of CHBG core outcomes Trials (%)
Number of trials reported zero core outcome
Number of trials reported one core outcome
Number of trials reported two core outcome
Number of trials reported three core outcome
Number of trials reported four core outcome
37 (31.9)
46 (39.7)
23 (19.8)
6 (5.2)
4 (3.4)
CHBG: Cochrane Hepato-Biliary Group.
